 Receptor, ErbB-3
"Receptor, ErbB-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF RECEPTOR and the ERBB-2 RECEPTOR. Overexpression of the erbB-3 receptor is associated with TUMORIGENESIS.
| Descriptor ID |
D020893
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.500 D12.776.543.750.630.009.500 D12.776.543.750.750.400.074.500 D12.776.624.664.700.790 D23.101.140.721
|
| Concept/Terms |
Receptor, ErbB-3- Receptor, ErbB-3
- ErbB-3 Receptor
- Receptor, ErbB 3
- Proto-Oncogene Protein erbB-3
- Proto Oncogene Protein erbB 3
- erbB-3, Proto-Oncogene Protein
- erbB-3 Protein
- erbB 3 Protein
- HER-3 Proto-Oncogene Protein
- HER 3 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-3
- Tyrosine Kinase-type Cell Surface Receptor HER3
- Tyrosine Kinase type Cell Surface Receptor HER3
- Proto-Oncogene Proteins erbB-3
- Proto Oncogene Proteins erbB 3
- erbB-3, Proto-Oncogene Proteins
- Proto-oncogene-like Protein c-ErbB-2
- Protein c-ErbB-2, Proto-oncogene-like
- Proto oncogene like Protein c ErbB 2
- c-ErbB-2, Proto-oncogene-like Protein
- c-erbB-3 Protein
- c erbB 3 Protein
- Proto-Oncogene Protein c-erbB-3
- Proto Oncogene Protein c erbB 3
- c-erbB-3, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-3 [D08.811.913.696.620.682.725.400.009.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-3 [D12.776.543.750.630.009.500]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-3 [D12.776.543.750.750.400.074.500]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-3 [D12.776.624.664.700.790]
- Biological Factors [D23]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-3 [D23.101.140.721]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-3".
This graph shows the total number of publications written about "Receptor, ErbB-3" by people in this website by year, and whether "Receptor, ErbB-3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 3 | 0 | 3 | | 2006 | 2 | 2 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2013 | 4 | 0 | 4 | | 2015 | 3 | 0 | 3 | | 2016 | 1 | 1 | 2 | | 2017 | 0 | 4 | 4 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, ErbB-3" by people in Profiles.
-
Paterson C, Cumming B, Law AJ. Temporal Dynamics of the Neuregulin-ErbB Network in the Murine Prefrontal Cortex across the Lifespan. Cereb Cortex. 2020 05 14; 30(5):3325-3339.
-
Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019 08; 24(8):1095-1102.
-
He L, Du Z, Xiong X, Ma H, Zhu Z, Gao H, Cao J, Li T, Li H, Yang K, Chen G, Richer JK, Gu H. Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Sci Rep. 2017 11 06; 7(1):14584.
-
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. J Natl Cancer Inst. 2017 11 01; 109(11).
-
Krischer JP, Lynch KF, Lernmark ?, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, Akolkar B. Genetic and Environmental Interactions Modify the Risk of Diabetes-Related Autoimmunity by 6 Years of Age: The TEDDY Study. Diabetes Care. 2017 09; 40(9):1194-1202.
-
Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89.
-
Mishra R, Foster D, Vasu VT, Thaikoottathil JV, Kosmider B, Chu HW, Bowler RP, Finigan JH. Cigarette Smoke Induces Human Epidermal Receptor 2-Dependent Changes in Epithelial Permeability. Am J Respir Cell Mol Biol. 2016 06; 54(6):853-64.
-
Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget. 2016 Jan 19; 7(3):2921-35.
-
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Boh?rquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2462-70.
-
Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol. 2015; 8(6):6143-56.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|